Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241288907 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Sara El Zaitouni und 16 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biology of Human Pathologies, Genomic Center of Human Pathologies, Department of Biology, Faculty of Sciences, Mohammed V University in…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, High-Throughput Nucleotide Sequencing, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
We retrospectively analyzed the next-generation sequencing (NGS) results from diagnosed NSCLC patients to identify and compare genomic alterations of NSCLC between Moroccan patients and the Cancer Genome Atlas (TCGA). We also aimed to investigate the distribution and frequency of concurrent genomic alterations.
Methods
From December 2022 to December 2023, a retrospective study of 76 formalin-fixed paraffin-embedded (FFPE) samples have been profiled using the Oncomine™ Precision Assay on the Ion Torrent™ Genexus™ Integrated Sequencer across the panel of 50 key genes that are applicable for the selection of targeted therapy.
Results
Seventy of the 76 FFPE sequenced samples carried at least one genetic alteration in the tested genes. The study identified 234 genetic alterations in 18 genes. Targetable genetic alterations in EGFR, KRAS, MET, BRAF, ALK, RET and ROS1 were identified in 84.3% of tumors. EGFR and KRAS mutations were frequently reported, occurring in 24.3% and 22.9% of cases, respectively. The untargetable genetic alterations were found in 74.3% of the specimens in FGFR3, TP53, ERBB2, PIK3CA, CDKN2A, PDL1, FGFR1, PTEN, CHEK2 and ERBB3. There were additional uncommon/rare mutations in EGFR, BRAF, RET and ROS1. Comparing the prevalence of selected mutated genes in the NSCLC patients from the TCGA database identified substantial differences in EGFR (24.3%, vs14.97%), KRAS (22.9%, vs 25.99%), and TP53 (34.3%, vs 50.94%). ALK, ROS1, and RET gene rearrangements were detected in 4.3% of the 70 tumors tested. The ALK/ RET/ MET/ ROS1/ EML4 fusions were detected in 11.4% of samples. Co-alterations occurred in 67.1% of specimens. Co-occurring driver gene mutations were observed in 44.3%. TP53 mutations co-occurred driver gene mutations in 30% of tumors. Three cases (4.3%) harbored concurrent FGFR3, TP53, and PIK3CA alterations.
Conclusion
Our results regarding the proportion of samples with actionable mutations demonstrate the value of NGS testing for NSCLC patients in a real-world clinical diagnostic setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biology of Human Pathologies, Genomic Center of Human Pathologies, Department of Biology, Faculty of Sciences, Mohammed V University in Rabat, Rabat, Morocco.
- Royal School of Military Health Service, Sequencing Unit, Laboratory of Virology, Center of Virology, Infectious and Tropical Diseases, Mohammed V Military Instruction Hospital, Faculty of Medicine and Pharmacy, Mohamme…
- Department of Pathology, Nations-Unites Pathology Center, Rabat, Morocco.
- Microbiology and Molecular Biology Team, Department of Biology, Faculty of Sciences Mohammed V University in Rabat, Rabat, Morocco.
- Laboratory of Microbiology, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
- Laboratory of Biostatistics, Clinical Research and Epidemiology, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
ORCID-Profile: Sara El Zaitouni
Zitieren
APA
El Zaitouni, S., Laraqui, A., Ghaouti, M., Benzekri, A., Kettani, F., Boustany, Y., Benmokhtar, S., Lamrani Alaoui, H., El Annaz, H., Abi, R., Tagajdid, M. R., El Kochri, S., El Mchichi, B., Bouaiti, E. A., Lahlou, I. A., El Hassani, R. A., & Ennibi, K. (2024). Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241288907
Vancouver
El Zaitouni S, Laraqui A, Ghaouti M, Benzekri A, Kettani F, Boustany Y, et al. Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241288907
BibTeX
@article{ElZaitouni2024,
author = {El Zaitouni, Sara and Laraqui, Abdelilah and Ghaouti, Meriem and Benzekri, Asmae and Kettani, Fouad and Boustany, Youssra and Benmokhtar, Soukaina and Lamrani Alaoui, Hafsa and El Annaz, Hicham and Abi, Rachid and Tagajdid, Mohamed Rida and El Kochri, Safae and El Mchichi, Bouchra and Bouaiti, El Arbi and Lahlou, Idriss Amine and El Hassani, Rabii Ameziane and Ennibi, Khalid},
title = {Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241288907}
}
EUVIMED